Figure 6
Figure 6. Crenolanib activity against TKI-resistant pediatric AML primary blasts ex vivo. Primary blast samples were treated with DMSO or increasing concentrations of crenolanib or sorafenib for 72 hours. Cell viability measurements represent the mean ± SEM of 4 replicates.

Crenolanib activity against TKI-resistant pediatric AML primary blasts ex vivo. Primary blast samples were treated with DMSO or increasing concentrations of crenolanib or sorafenib for 72 hours. Cell viability measurements represent the mean ± SEM of 4 replicates.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal